How long you can live with lymphoma depends heavily on the type you have, the stage at diagnosis, and your age. Many people with lymphoma live for decades after diagnosis, and a significant number are permanently cured. The overall 5-year survival rate for Hodgkin lymphoma is about 89%, while non-Hodgkin lymphoma sits at 74.3%. But these broad numbers only tell part of the story.
Hodgkin Lymphoma Has High Cure Rates
Hodgkin lymphoma is one of the most treatable cancers. Five-year relative survival rates, based on data from 2016 to 2022, are strong across all stages. When the disease is confined to a single region, the 5-year survival rate is about 93%. When it has spread to nearby lymph nodes (regional stage), the rate actually edges up to 95%, likely because regional-stage cases respond well to standard treatment. Even when the disease has spread widely (distant stage), the 5-year survival rate is still 84%.
Many people live well beyond five years. A study from the Kentucky Cancer Registry found 10-year overall survival rates of roughly 81% for early-stage Hodgkin lymphoma patients receiving combined treatment. The American Cancer Society notes that many patients are effectively cured, meaning their lymphoma never returns.
Non-Hodgkin Lymphoma Varies More by Subtype
Non-Hodgkin lymphoma (NHL) is actually a large family of over 60 different cancers, which is why survival statistics span a wider range. The overall 5-year relative survival rate is 74.3%. Broken down by stage:
- Stage I (single region): 87.6%
- Stage II (multiple regions): 79.7%
- Stage III (both sides of the diaphragm): 74.0%
- Stage IV (widespread): 63.6%
The distinction between slow-growing (indolent) and fast-growing (aggressive) subtypes matters more than stage alone. Follicular lymphoma, the most common indolent type, has a median survival of 8 to 15 years even in advanced stages. It tends to be manageable for a long time, though it often comes back after treatment. Patients with zero or one risk factor have a 10-year survival rate of 67%.
Diffuse large B-cell lymphoma (DLBCL), the most common aggressive type, behaves differently. It grows quickly and needs intensive treatment, but more than 70% of patients with aggressive NHL can be cured with combination chemotherapy. The key difference: indolent lymphomas are often lived with for years but rarely cured outright, while aggressive lymphomas are more dangerous up front but more likely to be permanently eliminated.
Age Is One of the Strongest Predictors
Your age at diagnosis significantly affects outcomes. Five-year relative survival rates for non-Hodgkin lymphoma by age group paint a clear picture:
- Under 15: 91.3%
- 15 to 39: 85.9%
- 40 to 64: 80.8%
- 65 to 74: 74.2%
- 75 and older: 57.2%
This drop isn’t entirely because older bodies handle lymphoma worse. Older patients are more likely to have other health conditions that limit treatment options, and they tolerate intensive chemotherapy less well. The gap between someone diagnosed at 35 and someone diagnosed at 75 is nearly 30 percentage points.
What Determines Your Individual Outlook
Doctors use a scoring system called the International Prognostic Index to estimate how aggressive NHL will behave in a specific patient. It looks at five factors: age 60 or older, elevated levels of a blood enzyme called LDH (which signals faster cell turnover), poor physical functioning, stage III or IV disease, and cancer in more than one location outside the lymph nodes. The more of these factors present, the lower the predicted survival. Someone with none or one risk factor has a substantially better outlook than someone with four or five.
For follicular lymphoma specifically, how quickly the cancer returns after treatment is a major signal. If the disease comes back within 24 months of initial treatment, the prognosis drops sharply, with 5-year overall survival falling to about 50% in that group. Patients who stay in remission beyond two years do much better.
The Two-Year Milestone
Research from the Mayo Clinic has identified a practical benchmark that many patients find reassuring. If you remain in remission with no disease events for two years after diagnosis, your risk of dying from lymphoma drops below your risk of dying from other common causes like heart disease or stroke. In other words, after two years of remission, your life expectancy starts to look much more like that of the general population. This holds true even though a small number of late relapses can still occur, because salvage treatments are often effective.
Newer Treatments Are Extending Survival
Treatment advances over the past decade have meaningfully improved outcomes, particularly for people whose lymphoma comes back or doesn’t respond to initial therapy. CAR T-cell therapy, which reengineers a patient’s own immune cells to attack lymphoma, has shown durable results. A study published in Blood Advances with 10 years of follow-up data found that 58% of all patients treated with CAR T-cell therapy were still alive at the 10-year mark. Among those who achieved a complete response (meaning no detectable cancer after treatment), the 10-year overall survival rate was 82%.
For patients with aggressive B-cell lymphomas that have relapsed, newer antibody-based therapies are also showing promise. In recent clinical trials, several new drug combinations roughly doubled median overall survival compared to older regimens, pushing it from around 13 months to over 22 months in patients with limited remaining options. These aren’t cures for most patients in that situation, but they represent real additional time.
Living With Lymphoma Long-Term
For people with indolent lymphomas that can’t be fully cured, the reality is often years or even decades of manageable disease. Follicular lymphoma patients may go through several rounds of treatment over their lifetime, with periods of remission in between. The median survival of 8 to 15 years is just the midpoint. Many patients live significantly longer, especially those diagnosed at younger ages or with fewer risk factors.
Long-term survivors of any lymphoma type do face some ongoing health considerations. Prior treatment, particularly radiation and certain chemotherapy drugs, raises the risk of heart problems and secondary cancers years down the line. These late effects are a real part of the picture, but for most survivors, the overall trajectory is positive. The combination of better initial treatments, effective salvage options for relapse, and improved supportive care means that more people are living longer with lymphoma than at any previous point.